{"product_id":"andecaliximab-elisa-kit","title":"Andecaliximab ELISA Kit","description":"\u003cp\u003e\u003cb\u003eSize\u003c\/b\u003e:96T\u003c\/p\u003e\u003cp\u003e\u003cb\u003eApplications\u003c\/b\u003e:ELISA\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAccession\u003c\/b\u003e:P14780\u003c\/p\u003e\u003cp\u003e\u003cb\u003eStability and Storage\u003c\/b\u003e:The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eDetection method\u003c\/b\u003e:Colorimetric\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSample type\u003c\/b\u003e:Plasma, Serum\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAssay type\u003c\/b\u003e:Quantitative\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSensitivity\u003c\/b\u003e:0.156 μg\/ml\u003c\/p\u003e\u003cp\u003e\u003cb\u003eRange\u003c\/b\u003e:0.31-5 μg\/mL\u003c\/p\u003e\u003cp\u003e\u003cb\u003eRecovery\u003c\/b\u003e:80-120%\u003c\/p\u003e\u003cp\u003e\u003cb\u003eProperties\u003c\/b\u003e:\u003c\/p\u003e\u003cp\u003e\u003cb\u003eExperimental Procedure\u003c\/b\u003e:\u003c\/p\u003e\u003cp\u003e\u003cb\u003eBackground\u003c\/b\u003e:Andecaliximab (formerly GS-5745; Gilead Sciences, Inc.), a recombinant chimeric IgG4 monoclonal antibody (mAb), was engineered to remove T-cell epitopes to reduce immunogenicity risk. Andecaliximab selectively binds and inhibits matrix metalloproteinase-9 (MMP9) with minimal cross-reactivity to other matrix metalloproteinases, including the highly homologous matrix metalloproteinase-2 (MMP-2). Andecaliximab is under development for the treatment of cystic fibrosis, gastric cancer, pancreatic cancer, non-small cell lung cancer (NSCLC), rheumatoid arthritis (RA), Crohn's disease (CD), and ulcerative colitis (UC). In a recent phase 1 dose-escalation study in patients with UC, andecaliximab had good tolerability and was associated with a numerically greater percentage of clinical, endoscopic, and histological responses in patients relative to placebo over a 5-week treatment period. A phase 2\/3 trial, evaluating the safety and efficacy of andecaliximab to induce and maintain clinical remission in patients with moderate to severe UC, was initiated. A planned interim futility analysis following an 8-week induction period in the first 150 patients resulted in the termination of the study due to lack of efficacy.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAlternative Names\u003c\/b\u003e:GS-5745, 1518996-49-0\u003c\/p\u003e\u003cp\u003e\u003cb\u003eShipping\u003c\/b\u003e:2-8 ℃\u003c\/p\u003e\u003cp\u003e\u003cb\u003eNote\u003c\/b\u003e:For Research Use Only.\u003c\/p\u003e","brand":"GeneBio Systems","offers":[{"title":"Default Title","offer_id":48655943368804,"sku":"DB945018","price":659.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0558\/8588\/9636\/files\/no_image_default_image-jpeg_206fafc9-8a87-4bc6-bc54-aa92d154c3fb.jpg?v=1782808811","url":"https:\/\/www.genebiosystems.com\/en-gb\/products\/andecaliximab-elisa-kit","provider":"GeneBio ","version":"1.0","type":"link"}